Market Research Future
Advanced Wound Therapy Devices Market is expected to expand at 6.70% CAGR during the forecast period 2019 to 2023
Advanced Wound Therapy Devices Market – Scenario The global advanced wound therapy devices market is anticipated to touch a value of USD 2,804.53 million by 2023, asserts Market Research Future (MRFR). The market can showcase 6.70% CAGR from 2018 to 2023 (forecast period). Increasing incidence of diabetes is the primary driver of the market. Patients with diabetes have a slower healing rate and poor blood circulation which can negatively affect the immunity system. According to the Centers for Disease Control & Prevention (CDC), nearly 30.3 million in the U.S. suffer from diabetes. The advanced wound therapy devices market can expand by capitalizing on this trend and offering precise solutions. The growing numbers of the geriatric populace will be highly beneficial to the market. This is buttressed by the estimation by the World Health Organization (WHO) which pegs the elderly populace at 1.2 billion by 2025. Furthermore, development of novel products and rapid approval by regulatory bodies is projected to propel the advanced wound therapy devices market. For instance, ConvaTec got approval for its negative pressure wound therapy (NPWT) system by the U.S. FDA in 2018. The hydrofiber gels in the system lock the exudates and bacteria and offer a separate channel for the them to flow away from the wounded region.
Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/7421 Key Players Notable player names in the advanced wound therapy devices market are Cardinal Health (U.S.), ConvaTec Inc. (U.K.), Smith & Nephew plc (U.K.), Triage Meditech Pvt. Ltd. (India), Medela AG (Switzerland), Sechrist (U.S.), MĂślnlycke Health Care AB (Sweden), B. Braun Melsungen AG (Germany), DeRoyal Industries, Inc. (U.S.), Lohmann & Rauscher GmbH & Co. KG (Germany), Perry Baromedical (U.S.), and KCI Licensing, Inc. (U.S.).